Abstract: Provided herein are novel bifunctional compounds formed by conjugating EGFR inhibitor moieties with E3 ligase Ligand moieties, which function to recruit targeted proteins to E3 ubiquitin ligase for degradation. The disclosure also provides pharmaceutically acceptable compositions comprising compounds and methods for the treatment of EGFR mutant-related cancers.

Abstract: Systems, methods, and apparatuses disclosed herein can compensate for imbalances between multiple transport streams of an uplink (UL)-multiple-input and multiple-output (MIMO) transmission. These systems, methods, and apparatuses can adjust one or more signal metrics of multiple recovered transport streams of the UL-MIMO transmission that are received in the presence of imbalances between the multiple transport streams of the UL-MIMO transmission. As an example, these systems, methods, and apparatuses can inject noise into one or more of the multiple recovered transport streams to adjust the one or more signal metrics of the multiple recovered transmission streams to lessen the imbalances between the multiple transmission streams.

Abstract: The present invention relates to a crystalline form of (S)-7-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetr a-hydropyrazolo[1,5-a]pyrimi dine-3-carboxamide for inhibiting Btk, methods of preparation thereof and pharmaceutical compositions, and use of the crystalline form above in the treatment of a disease, or in the manufacturing of a medicament for the treatment of a disease.

Abstract: The present disclosure relates to the technical field of surveying and mapping building structures, in particular to a built-in gap measuring device and a gap measurement method. The built-in gap measuring device includes an adjustment mechanism and measuring mechanisms disposed on both sides of the adjustment mechanism. The adjustment mechanism can adjust the distance between two groups of measuring mechanisms, and the measuring mechanism includes a panel structure and a measuring column. The panel structure includes a bottom cover close to the adjustment mechanism and a top cover away from the adjustment mechanism. A plurality of rows of elastic column holes are arranged on the top cover in array, column seats in one-to-one correspondence with elastic column holes are arranged inside the panel structure in array.

Abstract: The present invention relates to salts of a PI3Kdelta inhibitor (referred to as “Compound A” hereinafter), preferably fumarate, and the crystalline forms thereof. The present invention also relates to the process of preparation and uses of the salts and crystalline forms of Compound A.

Abstract: Some aspects relate to apparatuses and methods for calculating an uplink pathloss in a wireless communication system. A user equipment (UE) can be configured to perform operations for calculating the uplink pathloss. The operations can include determining a transmission power of a physical uplink shared channel (PUSCH) transmission for a UE, TxpPUSCH, where the PUSCH transmission is from the UE to a base station. The operations can further include determining a receiving power of a sounding reference signal (SRS) by the base station, Rxpsrs; and further calculating the uplink pathloss based on the transmission power of the PUSCH transmission TxpPUSCH and the receiving power of the SRS Rxpsrs.

Abstract: The present invention relates to a crystalline form of (S)-7-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetr a-hydropyrazolo[1,5-a]pyrimi dine-3-carboxamide for inhibiting Btk, methods of preparation thereof and pharmaceutical compositions, and use of the crystalline form above in the treatment of a disease, or in the manufacturing of a medicament for the treatment of a disease.

Abstract: Systems and methods for enhanced power control at a user equipment (UE) under poor channel conditions respective to antenna transmit diversity (ATD) mechanisms are discussed herein. In some embodiments, a UE may reset a transmit power control (TPC) power adjustment value when an ATD antenna switch of the ATD mechanism is performed. In some embodiments, a UE may reduce the value of an ATD hysteresis timer upon determining that a reference signal receive power (RSRP) change on a monitored reference signal that drives a pathloss calculation at the UE exceeds a threshold. In some embodiments, a UE may scale a filtering coefficient of a pathloss calculation mechanism upon determining that an RSRP change on a monitored reference signal that drives a pathloss calculation at the UE exceeds a threshold.

Abstract: A gap measuring device is provided, which includes a base; a driving assembly including a first driving structure including a first moving part being capable of moving on the base in a first direction and a second driving structure being connected to the first moving part and including a second moving part being capable of moving in a second direction which is perpendicular to the first direction; and a measuring mechanism including a measuring rod bracket, a first measuring rod and a second measuring rod, a first end of the first measuring rod being provided with a first detection head, a first end of the second measuring rod being provided with a second detection head, a second end of the second measuring rod being provided with a pointer, the first detection head and the second detection head being located on the same side of the measuring rod bracket.

Abstract: This disclosure relates to techniques for multi-RAT and DSDA capable wireless devices to handle frame blanking in a wireless communication system. A wireless device may establish wireless links according to a first radio access technology and a second radio access technology. The wireless device may determine to perform transmit and receive blanking for one or more antennas of the wireless device for the first radio access technology to perform sounding reference signal transmissions for the second radio access technology based at least in part on a band combination for the wireless links. The wireless device may determine a modification to channel state feedback reporting for the first radio access technology based at least in part on the transmit and receive blanking. The wireless device may perform channel state feedback reporting using the determined modification.

Abstract: The present invention relates to a crystalline form of (S)-7-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetra-hydropyrazolo[1,5-a]pyrimidine-3-carboxamide for inhibiting Btk, methods of preparation thereof and pharmaceutical compositions, and use of the crystalline form above in the treatment of a disease, or in the manufacturing of a medicament for the treatment of a disease.

Abstract: Disclosed is a compound of Formula (I), or a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, and pharmaceutical compositions comprising thereof. Also disclosed is a method of treating PI3K? related disorders or diseases by using the compound disclosed herein.

Abstract: Systems and methods for generating a load model having composite load components for electric power systems are disclosed which include acquiring state information at a bus of the electric power system, acquiring a training event record, and generating the load model by sequentially executing steps of determining a final load component composition for a predetermined composite load model structure referencing to both the state information and the training event record, and determining a plurality of final load parameters corresponding to the final load component composition and the predetermined load model structure also referencing to both the state information and the training event record.

Abstract: Disclosed herein is a compound of Formula (I) for inhibiting TYK2 and treating a disease associated with the undesirable tyk-2 activity (tyk-2 related diseases), a method of using the compounds disclosed herein for treating inflammatory or autoimmune disease, and a pharmaceutical composition comprising the same.

Abstract: This disclosure relates to geophysical exploration and seismic imaging, and more particularly to a seismic imaging method, system, and device based on pre-stack high-angle fast Fourier transform (FFT). The method includes: acquiring seismic data acquired during seismic exploration; extracting a common shot point gather from the seismic data followed by conversion into a frequency wavenumber domain common offset gather; calculating wave propagation angles; dividing an imaging region into a first region and a second region; solving constant coefficients of the first region and the second region; performing frequency-division layer-by-layer wavefield continuation on a frequency-wave number domain common offset gather to obtain imaging results at different depths and frequencies; subjecting the imaging results to integration followed by transformation to a spatial domain to obtain common offset imaging profiles; and subjecting the common offset imaging profiles to superposition obtain final imaging results.

Abstract: Systems, methods, and apparatuses disclosed herein can compensate for imbalances between multiple transport streams of an uplink (UL)-multiple-input and multiple-output (MIMO) transmission. These systems, methods, and apparatuses can adjust one or more signal metrics of multiple recovered transport streams of the UL-MIMO transmission that are received in the presence of imbalances between the multiple transport streams of the UL-MIMO transmission. As an example, these systems, methods, and apparatuses can inject noise into one or more of the multiple recovered transport streams to adjust the one or more signal metrics of the multiple recovered transmission streams to lessen the imbalances between the multiple transmission streams.

Abstract: The present invention relates to a crystalline form of (S)-7-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetra-hydropyrazolo[1,5-a]pyrimidine-3-carboxamide for inhibiting Btk, methods of preparation thereof and pharmaceutical compositions, and use of the crystalline form above in the treatment of a disease, or in the manufacturing of a medicament for the treatment of a disease.

Abstract: Disclosed herein are bifunctional compounds formed by conjugating EGFR inhibitor moieties with E3 ligase Ligand moieties, which function to recruit targeted proteins to E3 ubiquitin ligase for degradation of mutant EGFR kinase, and methods of preparation and uses thereof.